Haleon Launched GLP-1 Retail Strategy at CVS
The manufacturer created dedicated shelves for GLP-1 side-effect treatments, yielding a 24% boost in store sales.
Updated on Sept. 18, 2026 in Consumer Goods
Live Poll
Do you trust national brand health products enough to pay more than store-brand equivalents?
Haleon has implemented a retail strategy at CVS Pharmacy stores, placing its consumer health products on dedicated shelves targeting GLP-1 weight-loss drug users. The initiative resulted in a 24% average sales increase per store during the first quarter of 2026.
Why it matters
The company designed this targeted placement strategy to transform the management of common GLP-1 side effects into a primary revenue driver. By addressing symptoms like nausea and dry mouth directly, the firm seeks to capture value from the 11% of American adults currently utilizing these medications.
The retail strategy delivered a 24% sales lift per CVS store during the first quarter of 2026. Haleon currently maintains a market capitalization of approximately £29.67 billion as of September 17, 2026.
The players
Haleon
A global consumer healthcare company that separated from GlaxoSmithKline in 2022 and manufactures products like Advil and Sensodyne.
CVS Pharmacy
A major American retail pharmacy chain that collaborated with Haleon to implement dedicated shelf space for GLP-1 support products.
GlaxoSmithKline
A British multinational pharmaceutical and biotechnology company that formerly held ownership of the consumer healthcare division now known as Haleon.
The details
Haleon is leveraging its portfolio of well-known brands, including Advil, TUMS, Sensodyne, and Biotène, to provide relief for users experiencing nausea, vomiting, diarrhea, constipation, cramps, and dry mouth. CVS has simultaneously expanded its own product assortment to include both national and store-brand alternatives on these specialized destination shelves.
Timeline
Haleon separated from GlaxoSmithKline in 2022.
The retail strategy drove a 24% sales increase per store during Q1 2026.
Oral GLP-1 pills were introduced to the market in 2026.
Haleon revealed its new retail strategy on September 16, 2026.
Haleon shares were trading at 337.40 GBX on September 17, 2026.
Market Landscape
This strategy marks a shift toward specialized, condition-specific retail merchandising for major consumer goods companies. It positions Haleon to defend its market share against emerging store-brand products while capturing demand from the 29 million Americans using GLP-1 drugs.
Shoppers at CVS may notice more organized, condition-specific aisles that group health products by their utility for GLP-1 side effects. This convenience aims to streamline the purchase process for patients managing symptoms, though competitive store brands may offer lower prices.
The takeaway
Companies are increasingly segmenting store shelves to address the specific lifestyle needs of patients using emerging pharmaceutical treatments. Consumers benefit from a more intuitive shopping experience when seeking relief for specific drug-related side effects.
Further reading
For additional context on retail trends, visit the Consumer Goods section.
Source note: This article includes information reported by Idaho Statesman.
Live Poll
Do you trust national brand health products enough to pay more than store-brand equivalents?
